Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Obstructive Sleep Apnea
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: The researchers will do a trial of spironolactone in 30 obstructive sleep apnea (OSA) patients with cardiovascular disease who are non-adherent with Positive Airway Pressure (PAP) therapy.Masking: Double (Participant, Investigator)Masking Description: Both groups will receive treatment as usual for obstructive sleep apnea. Spironolactone and placebo will be prescribed by one of the study physicians (who will not be blinded to treatment condition ["care provider"]) .Primary Purpose: Supportive Care
Participation Requirements
- Age
- Between 18 years and 85 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04205136
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Louise O'Brien, PhD University of Michigan Principal Investigator: Bertram Pitt, MD University of Michigan Principal Investigator: J. Todd Arnedt, PhD University of Michigan